VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Gilead Sciences, Inc. vs Hims & Hers Health, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisHims & Hers Health, Inc.
HIMS · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Hims & Hers Health, Inc.'s moat claims, evidence, and risks.
View HIMS analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 51 / 100 for Hims & Hers Health, Inc.).
- Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); Hims & Hers Health, Inc. has 2 segments (97.4% in Online Platform).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
- Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; Hims & Hers Health, Inc. has 3 across 2.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Hims & Hers Health, Inc.
Online Platform
Direct-to-consumer telehealth + subscription pharmacy (cash-pay) for lifestyle and chronic conditions
Primarily United States
Consumers (end-users), paid out-of-pocket; supported by affiliated provider networks and pharmacy fulfillment
D2C digital health platform + fulfillment (mail-order pharmacy and partners)
97.4%
Side-by-side metrics
Moat coverage
Shared moat types
Gilead Sciences, Inc. strengths
Hims & Hers Health, Inc. strengths
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Hims & Hers Health, Inc. segments
Full profile >Online Platform
Competitive
Wholesale
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.